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Abstract: Staphylococcus aureus can develop resistance by mutation, transfection or biofilm for-
mation. Resistance was induced in S. aureus by growth in sub-inhibitory concentrations of ciprof-
loxacin for 30 days. The ability of the antimicrobials to disrupt biofilms was determined using crys-
tal violet and live/dead staining. Effects on the cell membranes of biofilm cells were evaluated by 
measuring release of dyes and ATP, and nucleic acids. None of the strains developed resistance to 
AMPs while only S. aureus ATCC 25923 developed resistance (128 times) to ciprofloxacin after 30 
passages. Only peptides reduced biofilms of ciprofloxacin-resistant cells. The antibiofilm effect of 
melimine with ciprofloxacin was more (27%) than with melimine alone at 1X MIC (p < 0.001). 
Similarly, at 1X MIC the combination of Mel4 and ciprofloxacin produced more (48%) biofilm 
disruption than Mel4 alone (p < 0.001). Combinations of either of the peptides with ciprofloxacin 
at 2X MIC released ≥ 66 nM ATP, more than either peptide alone (p ≤ 0.005). At 2X MIC, only 
melimine in combination with ciprofloxacin released DNA/RNA which was three times more than 
that released by melimine alone (p = 0.043). These results suggest the potential use of melimine and 
Mel4 with conventional antibiotics for the treatment of S. aureus biofilms. 
Keywords: Staphylococcus aureus; antibiotic resistance; biofilms; antimicrobial peptides;  
ciprofloxacin; combined effect 
 
1. Introduction 
Staphylococcus aureus is a major human pathogen that can cause several recalcitrant 
infections (deep-seated abscess, osteomyelitis, and endocarditis) due to the acquisition of 
antibiotic resistance and formation of biofilm on living tissues and medical devices [1,2]. 
Methicillin-resistant S. aureus (MRSA) has been named as a “serious threat” by the Center 
for Disease Control and Prevention [3,4]. Approximately 11,000 people die each year from 
a MRSA-related infection in the United States alone [5,6]. So far, there are limited reports 
on antimicrobial compounds that are able to control biofilm-associated infections caused 
by S. aureus [7]. 
Various strategies such as physical removal of materials colonized with bacteria or 
delivery of high doses of antibiotics at the site of infections have been used to treat biofilm-
associated infection [8]. However, due to poor penetration of antibiotics through the ex-
tracellular polysaccharide matrix of biofilms and survival of biofilm-embedded cells, even 
the use of high levels of antibiotics can result in low cure rates for infections [9]. Moreover, 
high doses of antibiotics may cause cytotoxicity to human cells. Therefore, combinations 
of different antimicrobials may be required [10]. 
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Several antimicrobial peptides (AMPs) are known to have strong antibiofilm activity 
against bacterial biofilms [11–13]. They can prevent bacterial attachment to surfaces (a first 
step toward biofilm formation) and destroy already developed biofilms by causing de-
tachment or killing of biofilm-embedded cells [11,13,14]. They can also enhance the activ-
ity of antibiotics against biofilms when used in combination [13,15–17]. These combined 
treatments may become an important part of treating biofilm-related infections, such as 
chronic wounds or biomaterial-associated infections caused by S. aureus [18]. In combina-
tion treatments, one mode of action that has been proposed is that the antibiotics bind to 
teichoic acids of staphylococcal cell wall which reduces the interaction with AMPs and 
facilitates their interaction with bacterial membranes. In this way, AMPs act on the cell 
membranes and antibiotics target cell wall and/or inhibit biosynthesis of nucleic acids and 
proteins [19,20]. 
Melimine (TLISWIKNKRKQRPRVSRRRRRRGGRRRR) and Mel4 
(KNKRKRRRRRRGGRRRR) are cationic AMPs which have a wide spectrum of activity 
targeting clinical isolates of Gram-negative and Gram-positive bacteria (including MRSA 
and multidrug-resistant P. aeruginosa), fungi and protozoa such as Acanthamoeba [21,22]. 
Both AMPs are non-cytotoxic at well above active concentrations [21,22]. Melimine causes 
hemolysis of horse red blood cells at concentrations 15 times higher than its minimum 
inhibitory concentration (MIC) [23] while Mel4 causes < 5% hemolysis even at concentra-
tions 17 times higher than its MIC [23]. Melimine and Mel4 can synergize with ciproflox-
acin against planktonic as well as biofilm forms of P. aeruginosa [24]. Ciprofloxacin is a 
broad-spectrum antibiotic, active against both Gram-positive and Gram-negative bacteria. 
Ciprofloxacin kills bacteria by binding to bacterial enzymes DNA gyrase and topoisomer-
ase IV. After binding, the enzyme undergoes conformational changes and breaks the 
DNA, and ciprofloxacin prevents religation of the broken DNA which ultimately stops 
DNA replication [25]. Both AMPs in combination with ciprofloxacin destroy P. aeruginosa 
biofilms at concentrations lower than their MICs [13]. Both AMPs act on the cell mem-
branes of planktonic cells of P. aeruginosa and this results in release of cellular contents 
[13]. However, it is not known whether peptides alone or in combination with antibiotics 
are active against S. aureus biofilms or can act in a similar way as they do to P. aeruginosa 
biofilms. The current study investigates the interaction of AMPs melimine or Me4 alone 
or in combination with ciprofloxacin against S. aureus biofilm in conjunction with their 
mode of activity. 
2. Results 
2.1. Minimal Inhibitory Concentration and Minimal Bactericidal Concentration 
Table 1 represents the MICs and MBCs values of both the peptides and ciprofloxacin. 
Melimine and Mel4 had the lowest MICs of 62.5 µg/mL and 125 µg/mL, respectively, 
against S. aureus ATCC 6538. For all other strains, there were slightly higher MICs, 125 
µg/mL for melimine and 250 µg/mL for Mel4, except for S. aureus ATCC 25923 for which 
Mel4 had the highest MIC value of 500 µg/mL (Table 1). Ciprofloxacin had similar MICs 
(0.5 µg/mL) and MBCs (1 µg/mL) against all the tested strains except for S. aureus ATCC 
6538 for which ciprofloxacin had the same MIC and MBC values of 0.5 µg/mL (Table 1). 
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Table 1. MIC and MBC values of melimine, Mel4 and ciprofloxacin against S. aureus. 
Bacterial Strains 












S. aureus 31 33.01 (125) 66.02 (250) 106.48(250) 212.96 (500) 1.50 (0.5) 3.01 (1) 
S. aureus 38 33.01 (125) 66.02 (250) 106.48 (250) 212.96 (500) 1.50 (0.5) 3.01 (1) 
S. aureus ATCC 6538 16.50 (62.5) 16.50 (62.5) 53.24 (125) 53.24 (125) 1.50 (0.5) 1.50 (0.5) 
S. aureus ATCC 25923 33.01 (125) 66.02 (250) 212.96 (500) 212.96 (500) 1.50 (0.5) 3.01 (1) 
MBC = minimum bactericidal concentration that kills ≥ 99.99% of bacteria of bacterial population compared to positive 
control; MIC = minimum inhibitory concentration that kills ≥ 90% of bacterial population when compared to the positive 
control. 
2.2. Development of Resistance to AMPs and Ciprofloxacin 
The growth curves of S. aureus ATCC 25923 at sub-MICs of melimine, Mel4 or ciprof-
loxacin over 24 h are presented in Figure 1. The growth of S. aureus ATCC 25923 at its sub-
MIC for ciprofloxacin was similar to growth without the antimicrobial. Melimine and 
Mel4 affected the growth rate of S. aureus after 6 h. Exposure to melimine resulted in 
slightly less growth than exposure to Mel4 over 24 h. 
 
Figure 1. Growth curves for S. aureus ATCC 25923 at sub-MIC of the antimicrobial peptides (AMPs) 
melimine and Mel4 or ciprofloxacin (Cipro). Melimine and Mel4 reduced the overall bacterial 
growth over 24 h of experiments while ciprofloxacin and the positive control (without any antimi-
crobial) had similar growth characteristics after 24 h experiment. 
Of all the tested strains, only S. aureus ATCC 25923 was able to develop resistance to 
ciprofloxacin. Changes in MICs of S. aureus ATCC 25923 after exposure to sub-MICs of 
melimine, Mel4 or ciprofloxacin over 30 days are presented in Figure 2. The MICs of 
melimine and Mel4 did not change over time, suggesting a limited potential of re-
sistance development to these peptides. Compared to the peptides, there was rapid de-
velopment of resistance to ciprofloxacin. Resistance developed to ciprofloxacin after 7 
days of serial passage with an initial 4-fold increase in MIC. The MIC increased 64-fold 
after 15 passages and 128-fold by 30 passages (Figure 2). 
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Figure 2. Increase in MIC values of ciprofloxacin, melimine or Mel4 against S. aureus ATCC 25923 
after exposing bacteria at their sub-MIC for 30 consecutive days. The MIC values of melimine and 
Mel4 did not change over time and overlap at the bottom of the figure. 
2.3. Inhibition of Biofilm Formation by AMPs and Ciprofloxacin Alone or in Combination 
Ciprofloxacin did not inhibit the biofilm formation of the ciprofloxacin-resistant cells 
of S. aureus ATCC 25923 at any concentration tested (p > 0.999; Figure 3A). Melimine and 
Mel4 inhibited biofilm formation at 0.5X MIC by 82% and 78%, respectively, compared to 
the negative control (p < 0.001). There was similar biofilm inhibition with both the AMPs 
at 0.5X MIC (p > 0.999). However, combined use of melimine with ciprofloxacin at 0.5X 
MICs resulted in 91% inhibition of biofilm, and this inhibition was significantly higher (p 
< 0.001) than the 82% produced by melimine alone at 0.5X MICs (Figure 3A). Similarly, 
Mel4 and ciprofloxacin in combination at 0.5X MIC produced 83% inhibition of biofilm 
which was significantly higher (p = 0.036) than the 78% produced by Mel4 alone (Figure 
3A). There was no significant difference in biofilm inhibition between melimine and 
ciprofloxacin, and Mel4 and ciprofloxacin combinations at 0.5X MIC (p > 0.999). 
The biofilms produced by the ciprofloxacin-sensitive cells of ATCC 25923 were in-
hibited by ≥ 86% by ciprofloxacin at ≥ 1X MIC (p < 0.001; Figure 3B). Melimine or Mel4 
were active at 0.5X MICs and produced 82% and 78% biofilms inhibition compared to 
negative control, respectively (p < 0.001). The combinations of melimine or Mel4 with 
ciprofloxacin at 0.5X MIC produced reductions that were significantly higher (97%) than 
those used alone at 0.5X (p < 0.001). The combinations of either AMP with ciprofloxacin 
inhibited the same amount of biofilm at 0.5X MICs (p > 0.999; Figure 3B). 
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Figure 3. Inhibition of biofilm formation of S. aureus ATCC 25923. Biofilm formation of the ciprofloxacin-resistant (A) or 
sensitive (B) cells of S. aureus ATCC was inhibited by various concentrations of melimine, Mel4 and ciprofloxacin alone or 
in combination. The strain was made resistant to ciprofloxacin by sub-passage for 30 days at a sub-MIC concentration. * 
represent significant (p < 0.001) decreases compared to the negative control (bacteria grown in the absence of antibiotics). 
# indicates significant (p < 0.001) decrease for the combinations compared to melimine or Mel4 alone while ## indicates p = 
0.036 compared to Mel4 alone. Means (±SD) of three independent repeats in triplicate. Negative control = bacteria grown 
in the absence of antimicrobials, Cipro = ciprofloxacin. 
2.4. Disruption of Pre-Formed Biofilms by AMPs and Ciprofloxacin Alone or in Combination 
In comparison to the effect of the AMPs or the combination of AMPs with ciproflox-
acin on preventing the production of biofilms, all were less active in reducing pre-formed 
biofilms. For melimine or Mel4 at 0.5X to 2X MIC, pre-formed biofilms of either the ciprof-
loxacin-resistant or sensitive cells were 4–6 times more resistant than the biofilms formed 
in the presence of melimine. 
The ability of AMPs and ciprofloxacin alone or in combination to disrupt pre-formed 
(24 h) biofilms of ciprofloxacin-resistant and sensitive isolates of S. aureus ATCC 25923 is 
presented in Figure 4. Ciprofloxacin did not reduce pre-formed biofilms of the ciproflox-
acin-resistant isolate of S. aureus ATCC 25923 at any of the concentrations tested (p > 0.999; 
Figure 4A). Both AMPs reduced the amount of pre-formed biofilms in a concentration-
dependent manner except at 0.5X MIC. Melimine produced 42%, 69% and 100% while 
Mel4 disrupted 38%, 64% and 97% at 1X, 2X and 4X MICs compared to negative control, 
respectively (p < 0.001; Figure 4A). Disruption of biofilm by melimine and Mel4 was sim-
ilar at their corresponding MICs (p > 0.999). The combination of melimine and ciprofloxa-
cin resulted in 69% biofilm disruption and the combination of Mel4 and ciprofloxacin re-
sulted in 86% biofilm disruption at their corresponding 1X MIC compared to negative 
control (p < 0.001). The combined treatment of either AMP with ciprofloxacin at 1X MIC 
resulted in similar biofilm disruption (p > 0.999). 
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Figure 4. Disruption of pre-established biofilm of S. aureus ATCC. Biofilms of the ciprofloxacin-resistant (A) and sensitive 
(B) cells of P. aeruginosa ATCC 27853 were disrupted at various concentrations by melimine, Mel4 and ciprofloxacin alone 
or in combination. * represents significant (p < 0.001), ** indicates significant (p = 0.005), *** indicates significant (p = 0.022) 
decrease compared to the negative control (biofilm treated with buffer). # indicates significant (p < 0.001) decrease for the 
combinations compared to melimine or Mel4 alone. Error bars represent means (±SD) of three independent repeats in 
triplicate. Negative control = bacteria grown in the absence of antimicrobials. Cipro = ciprofloxacin. 
Pre-formed biofilms of the ciprofloxacin-sensitive strain of S. aureus ATCC 25923 
were susceptible to the action of ciprofloxacin at 1X MIC or higher concentrations. Ciprof-
loxacin disrupted pre-formed biofilms in a dose-dependent manner by producing 86%, 
96% and 100% disruption of biofilms at 1X, 2X and 4X MICs, respectively, compared to 
control (p < 0.001; Figure 4B). Melimine disrupted 11% (p = 0.005) and Mel4 disrupted 10% 
(p = 0.022) of pre-formed biofilms compared to negative control at 0.5X MIC. At 1X MIC, 
melimine eradicated 41% of biofilm while Mel4 eradicated 37% of biofilm compared to 
buffer-treated negative controls (Figure 4B; p < 0.001). Interestingly, when AMPs were 
used in combination with ciprofloxacin, these combinations resulted in higher pre-formed 
biofilm disruption at concentrations lower than their MICs. The combination of melimine 
with ciprofloxacin at 0.5X MIC produced significantly higher (68%) biofilm disruption 
than when melimine (11%) was used alone at 0.5X (Figure 4B; p < 0.001). Similarly, the 
combination of Mel4 with ciprofloxacin at 0.5X MIC produced significantly higher (63%) 
biofilm disruption than when Mel4 (10%) was used alone at 0.5X (Figure 4B; p < 0.001). 
The combined treatment of either AMP with ciprofloxacin at 0.5X MIC resulted in similar 
biofilm disruption (p > 0.999). Similarly, at 1X MIC the combination of melimine with 
ciprofloxacin disrupted more highly (91%) than by melimine alone (41%) and Mel4 and 
ciprofloxacin disrupted more (89%) than by Mel4 alone (37%; p < 0.001). The combined 
antibiofilm effect of either peptide with ciprofloxacin was similar at 1X MIC (p > 0.999). 
2.5. Visualization of Biofilms 
Biofilms of the ciprofloxacin-resistant cells treated with buffer (HEPES) or ciproflox-
acin alone had an overall dimension of 90 µm by 90 µm by 21 µm and the cells were 
mainly green, indicating that they were alive (Figure 5). Biofilms treated with melimine 
or Mel4 at 4X their MICs had less biofilm mass with dimensions of 43 µm by 43 µm by 6 
µm and the cells were mainly stained red indicating many dead cells. No biofilms could 
be seen for the melimine and ciprofloxacin or Mel4 and ciprofloxacin combinations at 4X 
MICs (Figure 5). 
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Figure 5. Representative confocal laser scanning microscopy images of biofilms of the ciprofloxacin 
resistant isolates of S. aureus ATCC 25923 after treatment with AMPs and ciprofloxacin alone or in 
combination. The antibiofilm effects were evaluated at 4X the MIC of all antimicrobials after incu-
bation for 24 h. The biofilms of S. aureus were stained with SYTO-9 (excited at 488, green live cells) 
and propidium iodide (excited at 514 mm, red dead cells). The cells exposed to ciprofloxacin alone 
when excited at 514 nm had a reddish color indicating some of the cells had taken up the propidium 
iodide. 
2.6. Mechanistic Studies 
2.6.1. Cell Membrane Depolarization 
Melimine and Mel4 depolarized the cell membrane of S. aureus in biofilms in a con-
centration- and time-dependent manner (Figure 6A,B). Both peptides depolarized the cell 
membrane of biofilm cells within 1 h of incubation at 1X, 2X and 4X MICs. The fluores-
cence intensity produced as a result of the release of the DiSC3 (5) dye was higher at 4X 
than at 2X and 1X MIC for both melimine and Mel4 (p ≤ 0.004). The rate of release of the 
dye increased up to 2 h and became constant thereafter for all concentrations. There was 
no difference in release of dye between melimine and Mel4 at their corresponding MICs 
(p ≥ 0.999). Ciprofloxacin did not depolarize the cell membrane at any of the concentra-
tions tested over the entire 6 h of the experiment. The combined membrane depolarizing 
effect of melimine or Mel4 with ciprofloxacin was almost exactly equivalent to the 
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individual effects of melimine or Mel4 at their corresponding 1X, 2X, and 4X MICs (p > 
0.937; Figure 6A,B). There was no difference between the combinations at 1X and 2X MICs 
(p > 0.999). However, at 4X MIC, the melimine and ciprofloxacin combination caused 
higher membrane depolarization than the Mel4 and ciprofloxacin combination after 2 h 
of incubation (p = 0.005). The positive control (DMSO 20%) gave maximum fluorescence 
at 2 h which became constant following this time point. 
 
Figure 6. Cell membrane depolarization of pre-formed (24 h) biofilm cells. Cell membrane depolarization of S. aureus 
ATCC 25923 (became resistant to ciprofloxacin after 30 days of serial passages at sub-MIC) (A) by melimine and ciprof-
loxacin alone or in combination, and (B) by Mel4 and ciprofloxacin alone or in combination against pre-formed (24 h) 
biofilms. Error bars are means (±SD) of three independent repeats in triplicate. Cipro = ciprofloxacin, DMSO = dimethyl 
sulfoxide. 
2.6.2. Release of Cellular Contents 
Incubation of the AMPs with pre-formed biofilms of S. aureus ATCC 25923 released 
a substantial amount of ATP in a concentration-dependent manner (Figure 7). Melimine 
at 1X, 2X and 4X MIC induced leakage of 143 ± 15 nM, 167 ± 15 nM and 227 ± 21 nM ATP, 
respectively, compared to buffer-treated negative controls (p < 0.001). Mel4 at 1X, 2X and 
4X MICs released 107 ± 25 nM, 142 ± 13 nM and 197 ± 21 nM extracellular ATP, respec-
tively, compared to negative control (p ≤ 0.003). The amount of ATP released by melimine 
and Mel4 at their corresponding MICs was similar (p ≥ 0.999). The addition of ciprofloxa-
cin alone to pre-formed biofilms did not result in the significant release of extracellular 
ATP at any of the concentrations tested (p > 0.999; Figure 7). However, the combination of 
melimine or Mel4 with ciprofloxacin resulted in the release of higher amounts of ATP than 
the AMPs alone. At 2X MIC, the melimine and ciprofloxacin combination released signif-
icantly higher amounts of ATP (233 ± 38 nM; p = 0.005) than released by melimine alone 
(167 ± 15 nM). There was similar effect on ATP leakage of the combination at 2X and 4X 
MICs. The combination of Mel4 and ciprofloxacin at 1X, 2X and 4X concentrations induced 
leakage of 152 ± 24 nM, 203 ± 32 nM and 267 ± 12 nM ATP, respectively (Figure 7). At 2X 
MIC, the combination of Mel4 and ciprofloxacin released significantly higher amounts of 
ATP (p = 0.002) than was released by Mel4 alone at 1X MIC. Both the melimine and ciprof-
loxacin or Mel4 and ciprofloxacin combination had similar effects at their corresponding 
MICs (p > 0.999). 
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Figure 7. Leakage of ATP from pre-formed biofilm cells of S. aureus ATCC 25923. Leakage of ATP 
following treatment for 3 h with either of the two peptides and ciprofloxacin alone or in combina-
tion. The strain was made resistant to ciprofloxacin by passage for 30 days at a sub-MIC. * represents 
significant (p < 0.001) increases in the amount of extracellular at inhibitory concentrations of pep-
tides ATP compared to the negative control. # represents significant (p < 0.001) increase in the release 
of ATP of the combination of melimine or Mel4 with ciprofloxacin compared to melimine or Mel4 
alone. 
The release of nucleic acids (260 nm absorbing material) after incubation for 4 h with 
the antimicrobials from pre-formed biofilms of S. aureus ATCC 25923 is shown in Figure 
8A. Melimine released a significantly higher amount of DNA/RNA at 2X MIC (7 ± 1 times; 
p = 0.043) and 4X MIC (13 ± 1 times; p < 0.001) compared to control. Ciprofloxacin did not 
cause significant DNA/RNA leakage from the pre-formed biofilms at any concentration 
tested (p > 0.999; Figure 8A). The combination of melimine and ciprofloxacin released 10 
± 2 times (p = 0.047) more DNA/RNA compared to negative control at 2X MIC. Melimine 
and ciprofloxacin in combination released significantly higher (p = 0.022; Figure 8A) 
amounts of DNA/RNA than melimine alone at 2X MIC. The combination of Mel4 and 
ciprofloxacin did not release significant amounts of DNA/RNA at any concentration 
tested (p ≥ 0.480). Melimine either alone or in combination with ciprofloxacin produced 
higher fluorescence at 2X and 4X MICs than other concentrations (p ≤ 0.034; Figure 8B). 
Mel4 either alone or in combination with ciprofloxacin did not produce significant fluo-
rescence at any concentration tested (p > 0.999; Figure 8B). 
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Figure 8. Increase in OD260nm after release of DNA/RNA (A) and increase in fluorescence after interaction of Sytox green 
with released DNA/RNA (B) from pre-formed biofilm cells of S. aureus ATCC 25923. Leakage of nucleic acid from pre-
formed (24 h) biofilms of S. aureus ATCC 25923 following treatments for 3 h with either of the two peptides and ciproflox-
acin alone or in combination. The strain was made resistant to ciprofloxacin by passage of 30 days at a sub-MIC concen-
tration. * represents significance (p = 0.043) and ** indicates (p ≤ 0.034) release of nucleic acid compared to the negative 
control. # represents significant (p = 0.022) increase in the release of nucleic acid by the combination of melimine and 
ciprofloxacin compared to melimine alone. 
3. Discussion 
Exposure of bacteria to sub-inhibitory concentrations of antimicrobials can result in 
generation of resistant mutants [26,27]. The current study demonstrated that the AMPs 
melimine and Mel4 at sub-MICs did not induce resistance in S. aureus ATCC 25923. We 
and others [28–31] have tested several broad-spectrum antibiotics such as gentamicin 
(data not shown in the current study) and ciprofloxacin to determine whether strains such 
as S. aureus ATCC 6538, ATCC 25923, 31 and 38 can develop resistance to gentamycin and 
ciprofloxacin. Resistance to gentamicin or ciprofloxacin was not induced in any strain ex-
cept S. aureus ATCC 25923 which developed resistance against ciprofloxacin. Therefore, 
ciprofloxacin was selected to determine its activity alone or in combination with antimi-
crobial peptides against this strain. Biofilms of the resistance cells of S. aureus ATCC 25923 
could be reduced by treatment with combinations of melimine or Mel4 with ciprofloxacin 
whilst the biofilm was forming or once it had developed. 
S. aureus ATCC 25923 developed resistances to ciprofloxacin similar to P. aeruginosa 
ATCC 27853 [13], in a step-wise manner to full resistance (>120X MIC) after 25 days of 
passage. Resistance to ciprofloxacin in S. aureus can occur due to mutations in grlA/grlB 
and gyrA/gyrB genes, which encode the subunits of topoisomerase IV and DNA gyrase, 
respectively [32,33], or over expression of the membrane-associated protein NorA efflux 
pump which leads to increased transport of ciprofloxacin out of the bacterial cell [34]. 
Changes in these genes may occur randomly during exposure to ciprofloxacin and this 
may be why the resistance occurs sporadically during exposure to the antibiotic. In con-
trast to S. aureus ATCC 25923, all other S. aureus strains (31, 38 and ATCC 6538) did not 
mutate and develop resistance against ciprofloxacin. None of the S. aureus strains was able 
to develop resistance against melimine and Mel4. The inability of S. aureus to develop 
resistance against melimine and Mel4 may be due to the rapid killing kinetics of these 
peptides and action on cell membranes [23]. Bacteria appear to rarely gain resistance to 
AMPs that target bacterial membranes [23,35]. However, like other Gram-positive bacte-
ria, S. aureus can develop resistance to AMPs by reducing the negative charge on teichoic 
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acid and production of proteases that fragment AMPs [36,37], but these mechanisms ap-
pear not to have been activated during growth in sub-MICs of melimine or Mel4. 
Another mechanism whereby bacteria can protect themselves from the action of an-
timicrobials is formation of biofilms [38]. Melimine and Mel4 prevented biofilm formation 
of S. aureus at a concentration lower than their MICs. A similar effect has been shown with 
the cathelicidin-derived peptide NA-CATH:ATRA1-ATRA1 against S. aureus biofilm [39]. 
The AMPs esculentin-3, Tet-213 and 1010 peptides prevent biofilm formation [40,41] by 
stimulating twitching motility, influencing quorum sensing or degrading signaling mole-
cules such as ppGpp which lead to changes in the expression of genes related to biofilm 
assembly [42–44]. 
Melimine and Mel4 killed biofilm cells and dispersed pre-formed biofilms. Similarly, 
AMPs such as LL37, DL-K6L9, Seg5L, Seg5D, Seg6L, and Seg6D killed the biofilm cells 
and reduced the biofilm mass by dispersing the biofilm matrix [45,46]. Both our AMPs 
followed a similar mechanism, as treating biofilms of ciprofloxacin-resistant cells with ei-
ther AMP resulted in a high proportion of PI positive (stained red = dead cells) with a 
reduced biofilm mass compared to buffer-treated negative controls. Disruption of pre-
formed biofilm by these two AMPs was similar to disruption of pre-formed biofilm of P. 
aeruginosa [13]. Like the case with P. aeruginosa, the anti-biofilm effects of melimine and 
Mel4 against S. aureus were similar to their mode of action on S. aureus cells in suspension 
[23]; this is depolarization of membranes and release of intracellular contents. 
However, the speed of the effects of melimine and Mel4 was decreased compared to 
their effects on planktonic cells [13], which may be due to the complex structure of S. au-
reus biofilms hindering the antimicrobial action of AMPs. Membrane depolarization of 
biofilm cells caused by melimine and Mel4 was slower and happened after one hour com-
pared to only 30 s against planktonic bacteria [23]. Similarly, membrane depolarization of 
S. aureus cells in biofilms occurred after 1 h with the AMPs nisin A and lacticin Q [47]. The 
time required to depolarize the membrane of S. aureus biofilm cells was similar to P. aeru-
ginosa biofilm cells [13]. Slower membrane depolarization of biofilm cells compared to 
planktonic bacteria might be due to higher viscosity of biofilm which can affect the pene-
tration of AMPs in biofilm [47–49]. Moreover, negatively charged polymers of biofilms 
may interact with the positively charged AMPs and limit penetration and diffusion of 
AMPs in biofilm matrix. 
Both AMPs killed the biofilm cells by damaging the membranes followed by leakage 
of cellular ATP. Leakage of ATP from biofilm cells was slower and occurred after 3 h 
compared to after 2 min from planktonic bacteria [23]. As discussed above, this change in 
timing of events may be due to the charge of biofilm polymers or viscosity within biofilms. 
Higher concentrations of AMPs above their MICs may disrupt the membrane of biofilm 
cells to a greater extent and start to release larger molecules [48,50–52]. Melimine released 
DNA/RNA from biofilm cells at 4X MIC. On the other hand, Mel4 alone or in combination 
with ciprofloxacin did not result in release of DNA/RNA even at 4X its MIC. The mecha-
nism of action of Mel4 against biofilm cells seems to be similar to planktonic cells which 
are independent of the release of DNA/RNA [23]. 
The combination of AMPs and ciprofloxacin inhibited greater biofilm formation at 
0.5X than alone, suggesting that both the peptides may have additive or synergistic effects 
against S. aureus. The AMPs indolicidin, cecropin (1–7) and nisin in combination with 
ciprofloxacin inhibited the S. aureus biofilm at concentrations lower than their MICs [38]. 
The fractional inhibitory concentrations of these AMPs with ciprofloxacin were above syn-
ergistic levels, showing additive effects instead, against planktonic S. aureus [24]. The com-
bination of AMPs with ciprofloxacin resulted in more biofilm disruption at 1X MIC than 
alone. These results coincide with the previous study which reported that the AMPs in-
dolicidin, cecropin (1–7)–melittin A (2–9) and nisin in combination with teicoplanin or 
ciprofloxacin disrupted the biofilm of methicillin-resistant S. aureus at 1X MIC [53]. 
Smaller differences in biofilms inhibition/disruption may be due to sensitivity of the strain 
towards antibiotics, maturation of biofilms and concentration of antimicrobials used. 
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Several peptides in combination with antibiotics have been tested against biofilms formed 
for 2 h to 4 h, at concentrations 2–4 times lower than their MICs. Table 2 compares these 
combinations with melimine or Mel4 with ciprofloxacin tested at their 0.5X MICs against 
biofilms formed for 24 h in the present study. The slightly higher effects of the combina-
tion of Citropin1.1 + Minocycline [54] or LL37 + Teicoplanin [20] may be due to the fact 
the biofilms were only produced for 4 h, whereas the current study used biofilms formed 
over 24 h and these longer times might produce more robust biofilms. The effect of both 
the peptides with ciprofloxacin against S. aureus biofilm is summarized in Figure 9. The 
ability of the AMP-ciprofloxacin combinations to disrupt greater amounts of pre-formed 
biofilms might be related to AMPs’ facilitating higher intracellular uptake of ciprofloxacin 
[55]. The AMPs WR12, SAAP-148, SAAP-276 and TC84 allowed greater cellular uptake of 
ciprofloxacin and teicoplanin by permeabilizing the cell membrane of S. aureus in biofilms 
[20,55]. Another possible mechanism of AMP-antibiotic combinations is disrupting the 
biofilm matrix to allow AMPs to target the bacterial cells in the biofilm and cause disper-
sion of cells in the biofilm [56]. 
Table 2. Effect of antimicrobial peptides and antibiotics at 0.5X MIC in combination against S. au-
reus biofilm. 
Antimicrobial Agents Biofilm Inhibition (%) Biofilm Eradication (%) 
Melimine + Ciprofloxacin 91% 69% 
Mel4 + Ciprofloxacin 83% 86% 
Citropin1.1 + Minocycline [54] >99% ND 
Indolicidin + Daptomycin [53] 44% ND 
Nisin + Ciprofloxacin [53] 50% ND 
LL37 + Teicoplanin [20] ND >99% 
Temporin A +Gentamycin [57] ND 90% 
Indolicidin + Ciprofloxacin [38] ND 47% 
 
Figure 9. Effect of ciprofloxacin and peptides on the pre-formed biofilm of S. aureus. Ciprofloxacin alone did not disrupt 
the biofilm while when in combination with melimine or Mel4 it destroys the biofilm matrix following release of 
DNA/RNA (with melimine only) and ATP from biofilm cells. 
4. Materials and Methods 
4.1. Synthesis of Peptides and Bacteria 
Melimine and Mel4 were synthesized by conventional solid-phase peptide protocol 
[58,59] and were procured from the Auspep Peptide Company (Tullamarine, Victoria, 
Australia). The purity of the peptides was ≥90%. Ciprofloxacin was purchased from 
Sigma-Aldrich (St Louis, MO, USA). Ciprofloxacin stock solution (5120 µg/mL) in milli Q 
water was prepared and stored at −30 °C. Bacterial strains such as S. aureus 31 (mecA 
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positive) and S. aureus 38 (mecA negative; both microbial keratitis isolates) [60] and two 
reference strains S. aureus ATCC 6538 (mecA negative; a human lesion isolate) and S. au-
reus ATCC 25923 were used in the current study. 
4.2. Minimal Inhibitory Concentration and Minimal Bactericidal Concentration 
The minimum inhibitory and minimum bactericidal concentrations of ciprofloxacin 
were determined using a standard broth microdilution method of the Clinical Laboratory 
and Standard Institute (CLSI) and a modified version of the CLSI broth microdilution 
method was used to determine the MIC of antimicrobial peptides [61]. The MIC was set 
as the lowest concentration that reduced bacterial growth by ≥90% while the MBC was set 
as the lowest concentration that reduced bacterial growth by >99.99% following enumer-
ation of live bacteria by plate counts compared to bacteria grown in the absence of any 
antimicrobial. 
4.3. Growth Curve and Resistance Development at Sub-MIC of Antimicrobials 
An aliquot (100 µL) of an overnight culture (1 × 106 CFU/mL) of bacteria was added 
to an equal volume of each antimicrobial to achieve a sub-MIC (0.5X MIC) in MHB and 
was incubated at 37 °C with shaking at 120 rpm for 24 h. The turbidity of the bacterial 
suspensions was determined at OD660nm over time for 24 h. Bacteria grown in wells with-
out antimicrobials served as positive controls for maximum bacterial growth. Serial pas-
sages of S. aureus ATCC 25923 were performed in the presence of each antimicrobial at 
0.5X MIC. After incubation for 18–24 h, cells were repassaged into fresh media containing 
sub-MICs of the antimicrobials. After every passage, the MIC for each antimicrobial was 
determined, and a new sub-MIC was adjusted if any increase in MIC was observed. This 
repassaging lasted for 30 consecutive days. S. aureus 31, S. aureus 38, S. aureus ATCC 6538 
and S. aureus ATCC 25923 strains were exposed to AMPs and ciprofloxacin at sub-MIC 
(one-fold below the MIC) for their ability to develop resistance against these antimicrobi-
als. Of all the tested strains, only S. aureus ATCC 25923 was able to develop resistance to 
ciprofloxacin using this method. This strain has been shown to be able to develop re-
sistance to ciprofloxacin previously [28]. 
4.4. Inhibition of Biofilm Formation by AMPs and Ciprofloxacin Alone or in Combination 
Inhibition of biofilm formation by AMPs alone or in combination with ciprofloxacin 
was determined using S. aureus 25923 that had been passaged for one day (sensitive cells) 
or thirty days (resistant cells). First, 100 µL of S. aureus (1 × 106 CFU/mL) was dispensed 
into round-bottom 96-well microtiter plates containing serial dilutions (0.5X to 4X MIC) 
of melimine, Mel4 or ciprofloxacin. Then plates were incubated at 37 °C with shaking at 
120 rpm for 24 h. The combined effect of melimine or Mel4 with ciprofloxacin was deter-
mined after adding equal volumes of each at their corresponding MICs. Wells containing 
bacteria and MHB and treated with buffer served as negative controls. Following incuba-
tion, the media were removed, and wells were then carefully washed two times with 
HEPES buffer to remove non-adherent cells. Subsequently, biofilms were fixed with 200 
µL of 99% v/v methanol for 15 min and then plates were air dried. Finally, biofilms were 
stained with 200 µL of 1% w/v crystal violet dissolved in water for 5 min. Unbound crystal 
violet was rinsed off with tap water and plates were inverted to air dry. The crystal violet 
absorbed in biofilms was solubilized in 200 µL glacial acetic acid (33%, v/v), the released 
dye was moved to new well and the amount of dye released was determined spectroscop-
ically at OD600nm. The degree of biofilm inhibition was determined as a percentage of the 
biofilm produced by the negative controls (bacteria with no antimicrobials) using the fol-
lowing formulae [62]. 
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% biofilm of single or combined antimicrobial 
=
(OD600nm of negative control)  −  (OD600nm of individual or (combined) antimicrobials)
(OD600nm of negative control)
 × 100 (1) 
4.5. Disruption of Pre-Formed Biofilms by AMPs and Ciprofloxacin Alone or in Combination 
Biofilms were formed by adding 100 µL of S. aureus ATCC 25923 (1 × 106 CFU/mL) 
ciprofloxacin-sensitive or resistant cells into round-bottom 96-well microtiter plates con-
taining 100 µL of MHB. Plates were incubated at 37 °C in static condition. After incuba-
tion, biofilms were treated with serially diluted peptides or ciprofloxacin or their combi-
nation at their corresponding MICs and the plates were incubated for a further 24 h at 37 
°C in static condition. Wells containing bacteria and MHB and treated with buffer served 
as negative controls. Following incubation, the media were removed, and wells were then 
carefully washed two times with HEPES buffer to remove non-adherent cells and the 
amount of biofilm was determined as outlined in the previous experiment. 
The ability of each antimicrobial to disrupt pre-formed biofilms formed by resistant 
(30-day ciprofloxacin-passaged) S. aureus ATCC 25923 was visualized with confocal laser 
scanning microscopy (FV 1200, Olympus, Tokyo, Japan). A 24 h pre-formed biofilm on 
sterile round glass coverslips in polystyrene plates was treated with 200 µL of 4X-MIC of 
melimine, Mel4 or ciprofloxacin alone or in combination at 37 °C for 24 h. Thereafter, bio-
films were stained with Live/Dead BacLight bacterial viability kit (Invitrogen, Eugene, 
OR, USA) and examined with confocal microscopy. The resulting data were processed 
using the Image J software version 8 (Bethesda, MD, USA). 
4.6. Mechanistic Studies 
As both AMPs had similar antibiofilm effects against either 1-day or 30-day ciprof-
loxacin-passaged strains of S. aureus ATCC 25923, the 30-day ciprofloxacin-passaged cells 
were selected to evaluate the mechanism of action of both the AMPs and ciprofloxacin 
towards bacterial cells in biofilms. 
4.7. Effect on Cell Membranes 
The depolarizing effect on the cell membranes of biofilm-embedded cells was deter-
mined as described previously [48]. 
Briefly, 24 h formed biofilms were washed with 5 mM HEPES (pH 7.2) containing 20 
mM glucose and 100 mM KCl at pH 7.2. Then, biofilm cells were loaded with the mem-
brane potential sensitive dye DiSC3 (5) (4 µM; Sigma Aldrich, St Louis, MO, USA)) in 
HEPES for 1 h in dark. Release of DiSC3 (5) following addition of serially diluted 
melimine, Mel4 or ciprofloxacin alone or in combination at 1X, 2X and 4X their respective 
MICs was recorded at regular intervals up to 6 h. DMSO (20%; Merck, Billerica, MA, USA) 
was used as a positive control to achieve maximum membrane depolarization. 
4.8. Release of Cellular Contents 
The biofilm cells were incubated with serially diluted melimine, Mel4 or ciprofloxa-
cin alone or in combination at 1X, 2X and 4X their corresponding MICs. The supernatants 
were removed after 3 h and filtered through 0.22 µm pore membranes (Merck, Tullagreen, 
Ireland). Subsequently, the amount of extracellular of ATP was measured using a biolu-
minescence kit (Invitrogen, Eugene, OR, USA) according to manufacturer’s instructions. 
Buffer (HEPES)-treated samples were used as negative controls [47]. 
Similarly, supernatant was also analyzed for release of nucleic acids (DNA/RNA) 
[26]. The supernatants were centrifuged at 1300× g for 10 min and then filtered through 
0.22 µm pore membranes (Merck). The OD260nm of the filtrate was measured, and the re-
sults were expressed relative to the initial OD260nm of biofilms taken at 0 min. Furthermore, 
the presence of nucleic acids in the supernatants was also confirmed with Sytox green (5 
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µM Invitrogen, Eugene, OR, USA) as final concentration. An increase in fluorescence due 
to the interaction of Sytox green with nucleic acid was measured spectrophotometrically 
at an excitation wavelength of 480 nm and an emission wavelength of 523 nm. 
4.9. Statistical Analysis 
All experiments were performed in three independent assays. One-way analysis of 
variance (ANOVA) with Bonferroni’s corrections for multiple comparisons was used to 
compare differences between control and antimicrobial-treated cells. The data of cell 
membrane depolarization were analyzed using two-way ANOVA with Tukey’s test. A 
probability value of p < 0.05 was considered statistically significant. 
5. Conclusions 
In conclusion, S. aureus in suspension could not become resistant to melimine or Mel4 
following repeated exposure in sub-inhibitory concentrations of these AMPs. Whilst both 
AMPs inhibited biofilm formation, once S. aureus had produced a biofilm, the cells became 
more resistant to melimine or Mel4, although they could still act against the biofilms at 4X 
their MICs. Moreover, the combination of the AMPs and ciprofloxacin produced greater 
effects, possibly as a result of the AMPs damaging the cell membrane of biofilm cells 
which resulted in increased or facilitated uptake of ciprofloxacin. Future research should 
be conducted, using, for example, fluorescently labelled ciprofloxacin to examine whether 
the combination results in greater uptake of ciprofloxacin. 
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